4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
European Research Infrastructures for Poverty Related Diseases (EURIPRED)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
HIV/AIDS, Tuberculosis (TB) and Malaria alone account for more than six million deaths worldwide every year. Despite substantial efforts made in recent years, Poverty Related Diseases are still spreading. New therapeutic interventions are therefore urgently required to combat Poverty Related Diseases. The existence of a well-developed HIV/TB/Malaria infrastructure presents a prime opportunity to a ...
Voir le projet
18
Participants partenaires
TERMINÉ
First in Man Novel Anticancer Therapeutic based on Dependence Receptors Concept (HERMIONE-2MAN)
Date du début: 1 sept. 2013, Date de fin: 31 août 2016,
It is usually assumed that transmembrane receptors are inactive unless bound by their respective ligand. Against this dogma, the CLB proposed that some receptors may also be active in the absence of ligand and in this case trigger cell death. These receptors were called dependence receptors (DR) as their expression at the cell surface leads the cell to be dependent for its survival on ligand avail ...
Voir le projet
5
Participants partenaires
TERMINÉ
Combined Highly Active Anti-retroviral Microbicides (CHAARM)
Date du début: 1 janv. 2010, Date de fin: 30 juin 2015,
This proposal is for a large scale collaborative project in which we propose both to develop novel microbicides directed against new intracellular targets and to investigate novel combinations of highly active anti-retroviral drugs which may be particularly effective as microbicides. Combinations may enhance efficacy but equally importantly will increase the genetic barrier to the development of r ...
Voir le projet
34
Participants partenaires
TERMINÉ
EUROpean consortium on NEUTralising antibodies using gp41 (EURONEUT-41)
Date du début: 1 janv. 2008, Date de fin: 31 mars 2014,
There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry. The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed ...
Voir le projet